• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Inspections, Compliance, Enforcement, and Criminal Investigations

  • Print
  • Share
  • E-mail

Cephazone Pharma, LLC - Close Out Letter 6/21/12


Department of Health and Human Services' logoDepartment of Health and Human Services

Public Health Service
Food and Drug Administration
 Los Angeles District
Pacific Region
19701 Fairchild
Irvine, CA 92612M2506
Telephone: 949-608-2900
FAX: 949-608-4415


June 21, 2012

Mr. Avinash Ghanekar, Director of Operations
Cephazone Pharma, LLC
250 East Bonita Ave
Pomona, CA 91767

Dear Mr. Ghanekar:

The Food and Drug Administration has completed an evaluation of your written responses to the FDA483, results of our inspection conducted November 17, 2011, and corrective actions to our Warning Letter [WL # 34-11], dated April 25,  2011. Based on our evaluation, it appears that you have addressed the violation(s) contained in the Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.

This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.



Alonza E. Cruse, Director
Los Angeles District